Secondary Adrenal Insufficiency: Where Is It Hidden and What Does It Look Like?
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Adrenal failure secondary to hypothalamic-pituitary disease is a common although underestimated and underdiagnosed condition, with serious consequences. Corticotropin deficiency can be isolated or more frequently occur in association with other pituitary hormones deficiencies. The most frequent endogenous cause of secondary adrenal insufficiency (SAI) is a tumor of the hypothalamic-pituitary region, usually associated with panhypopituitarism secondary to tumor growth or to its treatment with surgery or irradiation. Less commonly, SAI is due to nontumoral disorders including infiltrative lesions, infective processes, vascular alterations, traumatic brain injury, empty sella or genetic disorders. Finally, long-term administration of exogenous glucocorticoids can determine secondary and/or tertiary hypoadrenalism acting at the hypothalamic level and leading to prolonged suppression of the hypothalamic-pituitary-adrenal axis. It is essential to perform validated diagnostic procedures in order to promptly diagnose hypoadrenalism so as to prevent an adrenal crisis. At the same time, diagnosis is complex as no single test has sufficient sensitivity to identify all patients with SAI. Therefore, clinical judgment and follow-up are crucial for the assessment of corticotropin deficiency. Patients with persisting suggestive symptoms and/or a clinical history of higher risk for adrenal insufficiency deserve careful subsequent reassessments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, this is true also for patients who have received an evening/bedtime dose of ≥5 mg of prednisone for more than a few weeks.”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [81]
In the citing paper
“Patients with intermediate or uncertain risk of HPA suppression include those who are taking 10 to 20 mg of prednisone/day for more than three weeks or any patient who has taken any dose < 10 mg of prednisone/day for more than a few weeks (but not as a single bedtime dose).”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [81]
In the citing paper
“Accordingly to the literature [81], in patients who have received a GC dose comparable with more than 20 mg of prednisone/day for more than three weeks, HPA suppression is “likely”.”
From Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis (2017) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
This paper’s reference list could not be split into single entries.
Adrenal insufficiency in corticosteroids use: systematic review and meta-analysis
Broersen, L. H. A., Pereira, A. M., Jørgensen, J. O. L., & Dekkers, O. M. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1218 · Cited by 456
Schlaghecke, R., Kornely, E., Santen, R. T., & Ridderskamp, P. (1992) · New England Journal of Medicine · doi:10.1056/nejm199201233260403 · Cited by 381
Hahner, S., Loeffler, M., Bleicken, B., Drechsler, C., Milovanovic, D., Fassnacht, M., Ventz, M., Quinkler, M., & Allolio, B. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0884 · Cited by 346
Treatment and Follow-Up of Clinically Nonfunctioning Pituitary Macroadenomas
Dekkers, O. M., Pereira, A. M., & Romijn, J. A. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0643 · Cited by 252
Ospina, N. S., Al Nofal, A., Bancos, I., Javed, A., Benkhadra, K., Kapoor, E., Lteif, A. N., Natt, N., & Murad, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1700 · Cited by 247
Delayed diagnosis of adrenal insufficiency is common: a cross-sectional study in 216 patients
Bleicken, B., Ventz, M., Quinkler, M., & Hahner, S. (2010) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181db6b7a · Cited by 242
Sherlock, M., Reulen, R. C., Alonso, A. A., Ayuk, J., Clayton, R. N., Sheppard, M. C., Hawkins, M. M., Bates, A. S., & Stewart, P. M. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1097 · Cited by 185
Radiation-induced hypopituitarism after cancer therapy: who, how and when to test
Darzy, K. H. (2009) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet1051 · Cited by 171
Fiad, T. M., Kirby, J. M., Cunningham, S. K., & McKenna, T. J. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb03011.x · Cited by 168
Jones, S. L., Trainer, P. J., Perry, L., Wass, J. A. H., Besser, G. M., & Grossman, A. (1994) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1994.tb03793.x · Cited by 159
Cited by
Treatment with synthetic glucocorticoids and the hypothalamus-pituitary-adrenal axis
Paragliola, R. M., Papi, G., Pontecorvi, A., & Corsello, S. M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102201 · Cited by 181
“Accordingly to the literature [81], in patients who have received a GC dose comparable with more than 20 mg of prednisone/day for more than three weeks, HPA suppression is “likely”.”
BackgroundSaverino, S., & Falorni, A. (2020) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2020.101379 · Cited by 66
Garmes, H. M., Boguszewski, C. L., Miranda, P. A. C., Martins, M. R. A., Correa‐Silva, S. R., Abucham, J., Musolino, N. R. D. C., Vilar, L., Portari, L. H. C., Gadelha, M. R., et al. (2021) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000335 · Cited by 31
“In addition, patients should carry an identification and emergency card and be encouraged to use medical alert bracelets (45,46,49).”
BackgroundInfluentialAdrenal Failure: An Evidence-Based Diagnostic Approach
Shaikh, S., Nagendra, L., Shaikh, S. S., & Pappachan, J. M. (2023) · Diagnostics · doi:10.3390/diagnostics13101812 · Cited by 23
Zhang, L., Spatari, S., & Sun, Y. (2020) · Applied Energy · doi:10.1016/j.apenergy.2020.115227 · Cited by 22
Metadata
- Authors
- Guaraldi, F., Karamouzis, I., Berardelli, R., D'Angelo, V., Rampino, A., Zichi, C., Ghigo, E., & Giordano, R.
- Affiliations
- University of Turin (IT)
- Venue
- Frontiers of hormone research
- Publisher
- S. Karger AG
- Published
- 2016
- Volume
- 46
- Pages
- 159-170
- ISSN
- 0301-3073 (ISSN-L)
- 1662-3762
- OpenAlex
- W2404734675
- Cited by
- 22
- References
- 26
- Citations by year
- 2026: 4 · 2025: 1 · 2024: 2 · 2023: 4 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 3 · 2017: 2
- FWCI
- 7.19
- Type
- book chapter
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- other-oa
- www.karger.com/Services/SiteLicenses (vor)
- www.karger.com/Services/SiteLicenses (tdm)
- Locations
- Frontiers of hormone research (publishedVersion)
- PubMed (publishedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pituitary Gland Disorders and Treatments
- Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
- Keywords
- secondary adrenal insufficiency, hypothalamic-pituitary disease, corticotropin deficiency, panhypopituitarism, pituitary tumors, adrenal crisis, hypothalamic-pituitary-adrenal axis, empty sella syndrome, adrenal insufficiency diagnosis
- MeSH terms
- Adrenal Insufficiency, Humans
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Secondary Adrenal Insufficiency: Where Is It Hidden and What Does It Look Like? https://app.cochat.ai/papers/10.1159/000443915
- The paper
- Guaraldi, F., Karamouzis, I., Berardelli, R., D'Angelo, V., Rampino, A., Zichi, C., Ghigo, E., & Giordano, R. (2016). Secondary Adrenal Insufficiency: Where Is It Hidden and What Does It Look Like? Frontiers of hormone research. https://doi.org/10.1159/000443915
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.